Elisa Agostinetto

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 23

Top Topics

Early Breast Cancer

Locally Advanced

Sentinel Lymph Node

Histone Deacetylase

Top Venues

NPJ breast cancer

JCO precision oncology

Journal of clinical medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Francesco Schettini, Eva Blondeaux, Chiara Molinelli, Raphaëlle Bas, Hee Jeong Kim, Antonio di Meglio, Rinat Bernstein Molho, Sabine C Linn, Katarzyna Pogoda, Estela Carrasco, Kevin Punie, Elisa Agostinetto, Nerea Lopetegui Lia, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Marion Acheritogaray, Alberta Ferrari, Shani Paluch-Shimon, Robert Fruscio, Wanda Cui, Stephanie M Wong, Claudio Vernieri, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Cynthia Villarreal Garza, De Marchis Laura, Fabio Puglisi, Leonor Vasconcelos de Matos, Monica Mariño, Luis Teixeira, Rossella Graffeo, Alessia Rognone, Alessandra Chirco, Nicoleta Antone, Yara G Abdou, Maximilian Marhold, Ivana Božović-Spasojević, Cortes Salgado Alfonso, Luca Carmisciano, Marco Bruzzone, Curigliano Giuseppe, Aleix Prat, Matteo Lambertini
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Cancer (2024)
Francesco Schettini, Eva Blondeaux, Chiara Molinelli, Raphaëlle Bas, Hee Jeong Kim, Antonio di Meglio, Rinat Bernstein Molho, Sabine C Linn, Katarzyna Pogoda, Estela Carrasco, Kevin Punie, Elisa Agostinetto, Nerea Lopetegui Lia, Kelly-Anne Phillips, Angela Toss, Christine Rousset-Jablonski, Marion Acheritogaray, Alberta Ferrari, Shani Paluch-Shimon, Robert Fruscio, Wanda Cui, Stephanie M Wong, Claudio Vernieri, Maria Vittoria Dieci, Alexios Matikas, Mariya Rozenblit, Cynthia Villarreal Garza, De Marchis Laura, Fabio Puglisi, Leonor Vasconcelos de Matos, Monica Mariño, Luis Teixeira, Rossella Graffeo, Alessia Rognone, Alessandra Chirco, Nicoleta Antone, Yara G Abdou, Maximilian Marhold, Ivana Božović-Spasojević, Cortes Salgado Alfonso, Luca Carmisciano, Marco Bruzzone, Curigliano Giuseppe, Aleix Prat, Matteo Lambertini
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study. Cancer 130 (16) (2024)
Flavia Jacobs, Elisa Agostinetto, Alessandra Solferino, Rosalba Torrisi, Giovanna Masci, Armando Santoro, Rita De Sanctis
Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib. Journal of clinical medicine 12 (5) (2023)
Elisa Agostinetto, David Venet, Michail Ignatiadis, Ekaterina Kalashnikova
Reply to S. Di Cosimo et al. JCO precision oncology 7 (2023)
Elisa Agostinetto, Evandro de Azambuja, Matteo Lambertini
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Elisa Agostinetto, Evandro de Azambuja, Matteo Lambertini
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Fran Ois P Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine J Piccart
Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. Nature communications 14 (1) (2023)
Elisa Agostinetto, Evandro de Azambuja, Matteo Lambertini
Reply to: PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 9 (1) (2023)
Laurence Buisseret, Delphine Loirat, Philippe Aftimos, Christian Maurer, Kevin Punie, Véronique Debien, Paulus Kristanto, Daniel Eiger, Anthony Goncalves, François Ghiringhelli, Donatienne Taylor, Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Fran Ois P Duhoux, Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado, Elisa Agostinetto, Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano, John Stagg, Marianne Paesmans, Denis Larsimont, Christos Sotiriou, Michail Ignatiadis, Martine J Piccart
Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial. Nature communications 14 (1) (2023)
Veronique Debien, Virginie Adam, Elisabeth Coart, Elisa Agostinetto, Theodora Goulioti, Chiara Molinelli, Amal Arahmani, Francesco Ravera, Martine Piccart
DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer. Future oncology (London, England) (2023)
Emma Zattarin, Daniele Presti, Luigi Mariani, Caterina Sposetti, Rita Leporati, Alice Menichetti, Chiara Corti, Chiara Benvenuti, Giovanni Fucà, Riccardo Lobefaro, Francesca Ligorio, Leonardo Provenzano, Andrea Vingiani, Marta Del Vecchio, Gaia Griguolo, Marianna Sirico, Ottavia Bernocchi, Antonio Marra, Paola Zagami, Elisa Agostinetto, Flavia Jacobs, Pierluigi di Mauro, Andrea Esposito, Carlo Alberto Giorgi, Luca Lalli, Laura Boldrini, Pier Paolo Berton Giacchetti, Ambra Carnevale Schianca, Valentina Guarneri, Rebecca Pedersini, Agnese Losurdo, Alberto Zambelli, Daniele Generali, Carmen Criscitiello, Curigliano Giuseppe, Giancarlo Pruneri, Filippo de Braud, Maria Vittoria Dieci, Claudio Vernieri
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors. NPJ breast cancer 9 (1) (2023)
Flavia Jacobs, Elisa Agostinetto, Chiara Miggiano, Rita De Sanctis, Alberto Zambelli, Armando Santoro
Hope and Hype around Immunotherapy in Triple-Negative Breast Cancer. Cancers 15 (11) (2023)
Flavia Jacobs, Elisa Agostinetto, Alessandra Solferino, Rosalba Torrisi, Giovanna Masci, Armando Santoro, Rita De Sanctis
Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib. Journal of clinical medicine 12 (5) (2023)
Elisa Agostinetto, Agnese Losurdo, Guilherme Nader Marta, Armando Santoro, Kevin Punie, Romualdo Barroso, Lazar Popovic, Cinzia Solinas, Marleen Kok, Evandro de Azambuja, Matteo Lambertini
Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer. Expert opinion on investigational drugs 31 (6) (2022)
Frédéric Cailleux, Elisa Agostinetto, Matteo Lambertini, Françoise Rothé, Hsin-Ta Wu, Mustafa Balcioglu, Ekaterina Kalashnikova, Delphine Vincent, Giulia Viglietti, Andrea Gombos, Andreas Papagiannis, Isabelle Veys, Ahmad Awada, Himanshu Sethi, Alexey Aleshin, Denis Larsimont, Christos Sotiriou, David Venet, Michail Ignatiadis
Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. JCO precision oncology 6 (2022)
Alberto Zambelli, Riccardo Sgarra, Rita De Sanctis, Elisa Agostinetto, Armando Santoro, Guidalberto Manfioletti
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets. Expert opinion on therapeutic targets 26 (6) (2022)
Elisa Agostinetto, Guilherme Nader Marta, Marianne Paesmans, Lieveke Ameye, Isabelle Veys, Laurence Buisseret, Patrick Neven, Donatienne Taylor, Christel Fontaine, Francois P Duhoux, Jean-Luc Canon, Hannelore Denys, Florence Coussy, Camille Chakiba, Joana Mourato Ribeiro, Martine Piccart, Christine Desmedt, Michail Ignatiadis, Philippe Aftimos
ROSALINE: a phase II, neoadjuvant study targeting ROS1 in combination with endocrine therapy in invasive lobular carcinoma of the breast. Future oncology (London, England) 18 (22) (2022)
Elisa Agostinetto, Lieveke Ameye, Samuel Martel, Philippe Aftimos, Noam Pondé, Christian Maurer, Sarra El-Abed, Yingbo Wang, Malou Vicente, Saranya Chumsri, Judith Bliss, Judith Kroep, Marco Colleoni, Fausto Petrelli, Lucia Del Mastro, Alvaro Moreno-Aspitia, Martine Piccart, Marianne Paesmans, Evandro de Azambuja, Matteo Lambertini
PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ breast cancer 8 (1) (2022)
Elisa Agostinetto, Filippo Montemurro, Fabio Puglisi, Carmen Criscitiello, Giampaolo Bianchini, Lucia Del Mastro, Martino Introna, Carlo Tondini, Armando Santoro, Alberto Zambelli
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives. Cancers 14 (9) (2022)
Elisa Agostinetto, Joseph Gligorov, Martine J Piccart
Systemic therapy for early-stage breast cancer: learning from the past to build the future. Nature reviews. Clinical oncology 19 (12) (2022)
Elisa Agostinetto, Flavia Jacobs, Véronique Debien, Alex De Caluwé, Catalin-Florin Pop, Xavier Catteau, Philippe Aftimos, Evandro de Azambuja, Laurence Buisseret
Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer. Cancers 14 (21) (2022)
Elisa Agostinetto, Véronique Debien, Guilherme Nader Marta, Matteo Lambertini, Martine Piccart-Gebhart, Evandro de Azambuja
CDK4/6 and PI3K inhibitors: A new promise for patients with HER2-positive breast cancer. European journal of clinical investigation 51 (7) (2021)
Elisa Agostinetto, Mattia Rediti, Danai Fimereli, Véronique Debien, Martine Piccart, Philippe Aftimos, Christos Sotiriou, Evandro de Azambuja
HER2-Low Breast Cancer: Molecular Characteristics and Prognosis. Cancers 13 (11) (2021)